Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
71
datasets available to search
ShareScore release 0.9.0
Dataset results
71 results for “dimethyl fumarate”
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
ClinicalTrials.gov study NCT02907177. IPD Sharing: Not stated. Countries: 20. Publications: 1.
Dimethyl Fumarate for Obstructive Sleep Apnea
ClinicalTrials.gov study NCT02438137. IPD Sharing: NO. Countries: 1. Publications: 19.
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
ClinicalTrials.gov study NCT01568112. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
ClinicalTrials.gov study NCT01873417. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
ClinicalTrials.gov study NCT01838668. IPD Sharing: Not stated. Countries: 5. Publications: 3.
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
ClinicalTrials.gov study NCT04221191. IPD Sharing: YES. Countries: 1. Publications: 1.
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
ClinicalTrials.gov study NCT04570670. IPD Sharing: NO. Countries: 0. Publications: 1.
Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.
ClinicalTrials.gov study NCT05959759. IPD Sharing: YES. Countries: 1. Publications: 1.
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
ClinicalTrials.gov study NCT03345940. IPD Sharing: UNDECIDED. Countries: 1. Publications: 9.
Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
ClinicalTrials.gov study NCT03092544. IPD Sharing: NO. Countries: 1. Publications: 2.
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
ClinicalTrials.gov study NCT02159573. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
ClinicalTrials.gov study NCT01930708. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Dimethyl Fumarate (DMF) Observational Study
ClinicalTrials.gov study NCT02047097. IPD Sharing: Not stated. Countries: 22. Publications: 3.
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
ClinicalTrials.gov study NCT02959658. IPD Sharing: NO. Countries: 1. Publications: 2.
Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis
<p><b>Objective: </b>To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort.</p> <p><b>Methods: </b>Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses.</p> <p><b>Results:</b> We included 1998 pregnancies from 1619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% CI 0.27-0.32), fell to 0.19 (0.14-0.24) in third trimester, and increased to 0.59 (0.51-0.67) in early postpartum. Among women who used fingolimod or natalizumab, ARR before pregnancy was 0.37 (0.28-0.49) and 0.29 (0.22-0.37), respectively, and increased during pregnancy. Intrapartum ARR decreased with preconception dimethyl fumarate use. ARR spiked after delivery across all DMT groups. Natalizumab continuation into pregnancy reduced the odds of relapse during pregnancy (OR 0.76 per month [0.60-0.95], p=0.017). DMT re-initiation with natalizumab protected against postpartum relapse (HR 0.11 [0.04-0.32], p<0.0001). Breastfeeding women were less likely to relapse (HR 0.61 [0.41-0.91], p=0.016). 5.6% of pregnancies were followed by confirmed disability progression, predicted by higher relapse activity in pregnancy and postpartum.</p> <p><b>Conclusion: </b>Women with MS prescribed natalizumab or fingolimod preconception had higher rates of intrapartum and postpartum relapse. In women considered to be at high relapse risk, use of natalizumab before pregnancy and continued up to 34 weeks gestation, with early re-initiation after delivery is an effective option to minimize relapse risks. Strategies of DMT use have to be balanced against potential fetal/neonatal complications.</p>
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
ClinicalTrials.gov study NCT02117050. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT02090413. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
ClinicalTrials.gov study NCT02217982. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
ClinicalTrials.gov study NCT02125604. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
ClinicalTrials.gov study NCT03870763. IPD Sharing: YES. Countries: 13. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.